Harrow, Inc. (HROW)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$38.54+0.73%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · HROW
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 275.6 | 272.3 | 199.6 | 130.2 | 88.6 | 72.5 | 48.9 | 51.2 | 41.4 | 26.8 | 19.9 | 9.7 | 1.7 | — | — | — |
| Total Revenues | — | — | — | — | — | — | — | — | — | 26.8 | 19.9 | 9.7 | 1.7 | — | — | — |
| Cost of Revenues | 73.6 | 67.9 | 49.2 | 39.6 | 25.4 | 18.2 | 14.5 | 16.7 | 16.5 | — | — | — | — | — | — | — |
| Gross Profit | 202.0 | 204.4 | 150.4 | 90.6 | 63.2 | 54.3 | 34.4 | 34.4 | 24.9 | 13.3 | 10.1 | 4.5 | 0.6 | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 175.7 | 152.9 | 129.1 | 83.1 | 58.2 | 41.3 | 31.2 | 33.1 | 29.2 | — | — | — | — | 6.1 | 3.0 | 0.8 |
| R&D Expenses | 29.0 | 20.9 | 12.2 | 6.7 | 3.1 | 11.1 | 2.4 | 2.1 | 0.8 | 0.4 | 0.7 | 0.3 | 0.2 | 1.6 | 1.3 | 0.1 |
| Operating Income | (2.7) | 30.5 | 8.8 | 0.4 | 1.9 | 1.6 | 0.4 | (4.8) | (5.2) | (12.2) | (15.9) | (14.8) | (10.1) | (7.7) | (4.2) | (0.9) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 24.2 | 22.8 | 21.3 | 7.2 | 5.4 | — | — | — | — | — | — | 0.0 | — | 0.0 | 0.1 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | — | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | (0.0) | — | 0.0 | 0.1 |
| Other Non-Operating Income / Expenses | — | (31.9) | (26.1) | (24.1) | (15.9) | (19.5) | (3.8) | 4.7 | 19.8 | (0.8) | (3.3) | (1.1) | 0.0 | — | — | — |
| Asset Writedown | — | 0.0 | — | 0.4 | — | — | — | — | — | 0.3 | — | — | 0.0 | — | — | — |
| EBT, Incl. Unusual Items | (33.4) | (1.4) | (17.3) | (23.7) | (14.0) | (17.9) | (3.4) | (0.1) | 14.6 | (12.9) | — | — | — | — | — | — |
| Income Tax Expense | — | 3.8 | 0.2 | 0.7 | 0.1 | 0.1 | 0.0 | — | (0.9) | (0.9) | (0.1) | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Income | ||||||||||||||||
| Minority Interest | — | — | — | — | — | — | (0.1) | (0.3) | — | — | — | — | — | — | — | — |
| Net Income | (37.2) | (5.1) | (17.5) | (24.4) | (14.1) | (18.0) | (3.4) | 0.2 | 14.6 | (12.0) | (19.1) | (15.9) | (10.1) | (7.6) | (5.4) | (1.0) |
| Per Share | ||||||||||||||||
| Basic EPS | (1.00) | (0.14) | (0.49) | (0.75) | (0.51) | (0.69) | (0.13) | 0.01 | 0.67 | — | — | — | — | — | — | — |
| Diluted EPS | (1.00) | (0.14) | (0.49) | (0.75) | (0.51) | — | (0.13) | 0.01 | 0.61 | — | — | — | — | — | — | — |
| Revenue per Share | 7.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 37.4 | 36.8 | 35.7 | 32.6 | 27.5 | 26.8 | 25.9 | 25.3 | 21.9 | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 37.4 | 36.8 | 35.7 | 32.6 | 27.5 | — | 25.9 | 26.5 | 23.8 | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | 32.4 | 10.7 | 2.0 | 3.4 | 3.3 | 2.3 | (2.9) | (3.6) | (10.8) | (14.8) | (14.6) | — | — | — | — |
| EBIT | (2.7) | 30.5 | 8.8 | 0.4 | 1.9 | 1.6 | 0.4 | (4.8) | (5.2) | (12.2) | (15.9) | (14.8) | (10.1) | (7.7) | (4.2) | (0.9) |
| Effective Tax Rate | — | — | — | -3.0% | -0.5% | -0.7% | -0.1% | — | -6.4% | 7.2% | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.